Jul 17, 2024 4:14pm EDT OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA’s Profit Share Payments
May 07, 2024 4:05pm EDT OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
Mar 28, 2024 8:55am EDT Labcorp Announces Acquisition of Select Assets of BioReference Health’s Diagnostics Business
Mar 05, 2024 8:52am EST AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
Feb 27, 2024 4:05pm EST OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
Feb 22, 2024 4:05pm EST OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
Jan 09, 2024 4:05pm EST OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes